Psilocybin-Assisted Therapy

What may be happening in the brain?

A 2024 brain-imaging study found that psilocybin temporarily disrupted familiar patterns of brain-network activity, including networks involved in our sense of self. Researchers are also investigating neuroplasticity, the brain’s ability to adapt and form new connections. These findings help explain possible mechanisms, but do not prove exactly why a person improves.

The accessible idea is that your usual mental patterns may temporarily become less fixed. A story such as “I am damaged” or “I need alcohol to relax” may feel less absolute. That can create room for another perspective, without guaranteeing lasting change.

Awareness is the beginning. Integration is the work.

From our founder’s lived experience, one of the most important lessons is that awareness can arrive quickly, while living differently afterwards takes practice. You may recognise a pattern clearly, then return home to the same relationships, habits and pressures. This personal perspective is part of the Hub’s voice, rather than proof of how treatment works for everyone.

Integration means making sense of the experience and exploring how it fits into everyday life. It may involve psychotherapy, reflection, recovery support, boundaries or changes to habits and relationships. Body-based or somatic work may be helpful for some people, although evidence for specific integration approaches is still developing.

Recognising the pattern is the beginning. Changing it takes support, practice and time.

Healing can unfold in layers

Some trials have found meaningful improvement after one psilocybin session. One experience can be significant without resolving every part of grief, trauma or addiction. Further therapy may uncover other difficulties, and change can continue over months or years.

Some people describe benefits from different psychedelic-assisted treatments at different stages. That does not establish that repeated dosing or switching medicines produces better outcomes. Psilocybin, MDMA and other substances have different effects, risks and evidence bases. Any further treatment needs individual clinical assessment through lawful pathways; more is not automatically better, but one individual session isn’t a magical pill.

The goal is to build a life that reflects what you have learned. Sometimes the next step is another clinically appropriate treatment. Often it is therapy, rest, relationships, movement, recovery support and time to put existing insights into practice.

In a 2023 randomised trial of 104 adults with major depressive disorder, a single 25 mg psilocybin dose with psychological support reduced depressive symptoms more than an active placebo, with benefits evident through six weeks. A separate trial of 233 adults with treatment-resistant depression found greater improvement at three weeks with 25 mg than with a 1 mg comparison dose. These are research protocols, not instructions for personal use.

In a trial for alcohol use disorder, heavy drinking occurred on approximately 9.7% of days in the psilocybin-and-psychotherapy group, compared with 23.6% in the active-placebo-and-psychotherapy group during the 32-week follow-up. Small controlled cancer studies also found improvements in anxiety and depression lasting several months.

These results deserve attention, but they need context. Many studies are small, participants are carefully selected, and people can often tell whether they received a psychedelic. Expectations may influence outcomes, and researchers are still working out how much benefit comes from the medicine, psychological support and the environment around treatment. Long-term outcomes and safety need further study.